ArticleFrontiers in immunology2026
IgG glycosylation dynamics in active lupus nephritis during the first year of immunosuppressive therapy.
Article in Frontiers in immunology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
11 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Introduction: Lupus nephritis (LN) is a severe manifestation of systemic lupus erythematosus (SLE) characterized by immune dysregulation and kidney inflammation. Alterations in immunoglobulin G (IgG) glycosylation are known to influence immune responses and have been implicated in autoimmune diseases, including SLE and LN. This study aimed to investigate longitudinal changes in IgG glycosylation in patients with active LN, from before treatment to one year after immunosuppressive therapy initiation. Methods: Serum samples were collected from 17 patients with LN at two time points, i.e., at active LN, prior to treatment initiation (baseline), and after 12 months of therapy. IgG was purified and subjected to detailed glycosylation analysis (total and fragment-specific) by capillary gel electrophoresis (CGE). Changes in glycosylation patterns between the two time points were assessed using linear mixed effects and regression models. Results: Significant alterations in IgG glycosylation were observed between the two time points. In total IgG, decreased sialylation and increased monogalactosylated structures were prominent. Fragment-specific analyses revealed divergent dynamics: the Fc region showed increased asialylation and a higher proportion of bisecting GlcNAc-containing glycans, consistent with a pro-inflammatory effector profile, while the Fab region exhibited increased digalactosylated glycans and decreased fucosylation, a pattern not mirrored in the Fc region or total IgG glycome. Discussion: These findings indicate pro-inflammatory longitudinal shifts in IgG glycosylation during the transition of LN from an active to a treated disease state. The study underscores the relevance of IgG glycosylation in LN pathophysiology and suggests that IgG glycosylation patterns change following immunosuppressive therapy for active LN, potentially reflecting ongoing disease-related immune processes despite improvement in conventional clinical parameters.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.